Long term efficacy and safety of Tenofovir in patients with severe and progressive acute hepatitis B

Background: Acute Hepatitis B has a low chronification rate in healthy adults, but can progress to fulminant hepatitis and liver failure in about 1 percent. Our aim was to evaluate the efficacy and safety of tenofovir as first-line treatment for patients with severe and progressive acute hepatitis B. Methods: Eleven patients hospitalized 2006 – 2012 with acute severe hepatitis B in our transplant centre were treated with tenofovir as monotherapy. Clinical outcome, treatment duration, biochemical and virological parameters during therapy were analysed. Results: Mean age of patients was 49 years, 6 men and 5 women…